載入...
Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity
Checkpoint blockade immunotherapy is now a first-line treatment option for patients with melanoma. Despite achieving objective responses in about half of patients, the exact immune mechanisms elicited and those required for therapeutic success have not been clearly identified. Insight into these mec...
Na minha lista:
| 發表在: | Cancer Immunol Immunother |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer Berlin Heidelberg
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6939620/ https://ncbi.nlm.nih.gov/pubmed/31104075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-019-02346-4 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|